Monthly Archives: April 2009

Industry Update • 4/3/2009

Epocrates appointed Rose Crane CEO Double Helix Consulting US appointed Ann Stuchiner to vice president Solara promoted Trudy Chiavelli to senior account executive Valeant Pharmaceuticals appointed Steve Stefano to its board of directors Endo Pharmaceuticals appointed Nancy J. Hutson to its board of directors Merkle appointed Jeff Wiltrout to vice president and client group leader […]
Posted in People | Tagged , , , , , , , | Leave a comment

The Regulation Wars

Last Friday, FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) issued 14 untitled letters to pharma companies as a result of online advertisements that appeared as sponsored links on search engine results pages. There were already plenty of guidelines on marketing to consumers being enforced by PhRMA, but now comes a crackdown on Internet […]
Posted in Marketing, Regulatory | Tagged , , | 2 Comments

Gilead Tops the BusinessWeek 50

The best-performing company of them all? Well, according to BusinessWeek, it’s a biopharmaceutical company, Gilead Sciences, which placed first in the annual BusinessWeek 50. The company posted some impressive numbers: a 48.6 percent pretax profit as a percentage of average invested capital (taken as an average of the last three years), 38.2 average annual sales […]
Posted in Strategy | Tagged , | Leave a comment

Wyeth v. Levine: Disrupting the labeling process

The recent and highly publicized Supreme Court decision in Wyeth v Levine brings into sharp focus an aggressive expansion of risk for pharmaceutical companies. Specifically, the ruling sets a precedent that approval of drug labels by the FDA does not protect against lawsuits in individual states. While FDA compliance has never been defined as comprehensive […]
Posted in Legal, Regulatory | Leave a comment
  • Categories

  • Meta